Sasha A. Singh, MSc, PhD, FAHA/LinkedIn
Nov 12, 2025, 10:54
Sasha Singh: Even Well-Known Biology Still Holds Secrets – New ATVB Findings on Lipoproteins
Sasha Singh, Director of Proteomics Research at the CICS, Brigham and Women’s Hospital, Harvard Medical School, posted on LinkedIn:
”I am very grateful to Drs Kanter and Vaisar for highlighting our recent study in ATVB, an American Heart Association Journal, demonstrating that (apo)lipoproteins circulate as ADP-ribosylated forms that accumulate in developing plaques. Our paper underscores that even a well-studied biology still hides many secrets, and that mass spectrometry is a powerful technology to unveil them.”
Read the full article here.
Title: Molecular ART in the Atherosclerotic Lesion: ADP-Ribosylation
Authors: Jenny E. Kanter, Tomáš Vaisa
Stay updated with Hemostasis Today.
AHA
American Heart Association
American Heart Association Journal
and Vascular Biology
Arteriosclerosis
Atherosclerosis
Atherosclerotic Lesions
Brigham and Women's Hospital
Harvard Medical School
Health
Hematology
Hemostasis
Hemostasis Today
Jenny E. Kanter
Medicine
Sasha Singh
thrombosis
Tomáš Vaisa
Vascular Biology
-
Feb 20, 2026, 17:35Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research